The Science and Faith Foundation (STOQ)
The Science and Faith Foundation (STOQ) is a foundation under Vatican law promoted by the Pontiﬁcal Council for Culture. The identity and mission of the foundation have their main Magisterial references in the Pastoral Constitution, Gaudium et Spes, in the talks of St. John Paul II and Benedict XVI on the relations between science and faith, particularly in the Encyclical Fides et Ratio. The Foundation aims to give continuity to the activities of Project STOQ, which emerged from the collaboration between the Pontiﬁcal Council for Culture and Pontiﬁcal Roman Universities following the Galileo Commission and the Jubilee of Scientists in the year 2000. Among the aims of the foundation are research and study of the themes of dialogue between science, philosophy and theology; realization of conferences and other activities of high cultural and scientiﬁc value, even at the popular level; and publication of works of merit on the main arguments of the science–faith dialogue.
Stem for Life Foundation
Stem for Life, a Cura Foundation (“SFLF”) is a nonsectarian, nonpartisan, tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code focused on creating a movement to accelerate the development of cell therapies. SFLF believes that cell therapy holds the promise to cure many of the world’s most debilitating illnesses as opposed to merely treating their symptoms. It represents a fundamental shift away from traditional drug treatment in favor of looking inside ourselves to understand and then amplify our bodies’ natural repair mechanisms. SFLF is firmly committed to advancing cell therapy research and development and its applications to improve the everyday lives of everyday people. To further this end, SFLF raises awareness and supports research and development efforts. SFLF was established in 2007. Expanding the foundation’s original focus on adult stem cell therapy alone, the foundation’s board of trustees and staff are deeply committed to the considerable promise to improve human health, increase the quality of life, and enhance patient care offered by the broader field of cell therapy.
Sanford Health, one of the largest health systems in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South Dakota, the organization includes 44 hospitals, 1,400 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and nine countries. Nearly $1 billion in gifts from philanthropist Denny Sanford have transformed how Sanford Health improves the human condition.
For information, visit sanfordhealth.org or Sanford Health News.
John Templeton Foundation
Founded in 1987, the John Templeton Foundation supports research and dialogue on the deepest and most perplexing questions facing humankind. The Foundation funds work on subjects ranging from black holes and evolution to creativity, forgiveness, and free will. It also encourages civil, informed dialogue among scientists, philosophers, theologians, and the public at large.
With over $2.8 billion in assets and annual grants of $115 million in 2018, the Foundation ranks among the 25 largest grantmaking foundations in the United States. Headquartered outside Philadelphia, its philanthropic activities have engaged all major faith traditions and extended to more than 190 countries around the world.
Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies derived from the postpartum human placenta. Using proprietary technology in combination with its IMPACT™ platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases.
To learn more, please visit www.celularity.com.
The Leona M. and Harry B. Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust takes a rigorous, results-oriented approach to improving lives. We support exceptional efforts in the U.S. and around the world in health and select place–based initiatives, taking risks that others cannot. Our Type 1 Diabetes (T1D) Program is the largest private funder of T1D-related research and care. We collaborate across the T1D ecosystem, with both the private and public sectors, to leave no angle unexamined in pursuit of preventing and delaying T1D, and easing the daily burden of managing it today.
For additional information, please visit: www.helmsleytrust.org
Sorrento Therapeutics, Inc., is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MABTM library), clinical stage immuno-cellular therapies (CAR-T), intracellular targeting antibodies (iTabs), antibody-drug conjugates (ADC) and clinical stage oncolytic virus (Sephrevir®).
Sorrento’s commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TrpB1 agonist) non-opioid pain management small molecule in Resinferatoxin (RTX) and ZTido. RTX is completing a phase IB trial in terminal cancer patients. ZTido was approved by U.S. FDA on February 28, 2018
To learn more, please visit www.sorrentotherapeutics.com.
Hackensack Meridian Health
Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey.
Hackensack Meridian Health comprises 17 hospitals, which includes three academic medical centers, two children’s hospitals, nine community hospitals, a behavioral health hospital, and two rehabilitation hospitals.
Additionally, the network has more than 500 patient care locations which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 35,000 team members, and 7,000 physicians.
The Hackensack Meridian School of Medicine at Seton Hall University opened in 2018, the first private medical school in New Jersey in more than 50 years. The health network also formed a partnership with Memorial Sloan Kettering Cancer Center.
For additional information, please visit www.HackensackMeridianHealth.org.
T. Denny Sanford Institute for Empathy and Compassion at UC San Diego
At the University of California San Diego, we embrace a culture of exploration and experimentation. Case in point: Advances in brain imaging and the neurosciences allow previously unimaginable insights into the workings of the human mind, but not necessarily how to translate that knowledge into a benefit for patients or provider—until now, with the establishment of the T. Denny Sanford Institute for Empathy and Compassion at UC San Diego. The university has been shaped by exceptional scholars who are not afraid to look deeper, challenge expectations and redefine conventional wisdom. Established in 1960, UC San Diego’s rich academic portfolio includes six undergraduate colleges, five academic divisions and five graduate and professional schools. Ranked internationally as one of the top 20 research universities, we are driving innovation and change to advance society, propel economic growth and make our world a better place.
Learn more about UC San Diego’s Sanford Institute for Empathy and Compassion at compassion.ucsd.edu.
United Therapeutics Corporation
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens – having a positive impact on patients, the environment and society – will sustain our success in the long term.
Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.